![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SOLVAY ACQUIRES RIGHTS TO PRONOVA'S OMACOR FOR SEVERAL ASIAN COUNTRIES
SOLVAY ACQUIRES RIGHTS TO PRONOVA'S OMACOR FOR SEVERAL ASIAN COUNTRIES
September 26, 2005
Solvay SA said it signed an agreement with Norway's Pronova Biocare giving Solvay Pharmaceuticals exclusive distribution rights for Pronova's Omacor in India, Pakistan, Sri Lanka, Thailand, Vietnam, Singapore, Malaysia, China, Hong-Kong and New Zealand. This is a major territorial expansion to Solvay's current Omacor franchise, which includes greater Europe and the Middle East, it said. Omacor is registered by Pronova/Solvay Pharmaceuticals in more than 30 countries for adjuvant treatment in secondary prevention after myocardial infarction and for treatment of increased blood triglyceride levels or hypertriglyceridemia, the Belgian company said.
Forbes (http://www.forbes.com/markets/feeds/afx/2005/09/26/afx2242804.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct